• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Tel Aviv Listed Marijuana Stocks

April 13, 2017

 

As many of you may have noticed, there's been more and more going on in Israel surrounding the world of cannabis research and more. Israel has been home to biotech and pharmaceutical industry giants for quite some time now, such as Teva Pharmaceuticals' (NYSE:TEVA) research and development (R&D) operations. 

 

We're not concerned with companies like Teva Pharmaceuticals until they start looking further into the cannabinoid-based treatment of serious ailments. Until then, we're concerned with companies like Therapix Biosciences Ltd. (TASE:TRPX) (NASDAQ:TRPX) that are based in Israel, and focused on developing cannabinoid-based drugs.

 

According to the company's description, "Therapix has initiated two internal drug development programs based on repurposing a U.S. Food and Drug Administration approved synthetic cannabinoid (dronabinol). These two developments include: Joint Pharma developing THX-TS01 targeted to the treatment of Tourette Syndrome, and BrainBright Pharma developing THX-ULD01 targeted to the high value and under-served market of mild cognitive impairments."

 

Not only is Therapix based in Israel, but it also trades on the Tel Aviv Stock Exchange. In addition to the company's listing in Tel Aviv, the company just recently offered American Depository Shares (ADSs) on the Nasdaq. The underwriters of the offering on the Nasdaq also fully exercised their over-allotment options entitling them to purchasing an additional 300,000 ADSs, signaling heavy investor demand for the Israeli-based company.  

 

While there are not many cannabis companies listed on the Tel Aviv Stock Exchange right now, we expect more to seek capital in the public markets as they get further into the development stages regarding cannabinoid drugs. Bringing a drug to market is an extremely capital-intensive process, and offering shares to the public is one of the commonly used methods for raising the funds. 

 

D/M/O

 

Now read about how Israel is leading the charge in cannabinoid research  

Read more articles tagged:

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.